Brief: Jacobio Pharmaceuticals Says It Got IND Approval Of Cd73 Mab Jab-Bx102 From Center For Drug Evaluation In China
25/03/2022 13:21
March 25 (Reuters) - Jacobio Pharmaceuticals Group Co Ltd
1167.HK :
* GOT IND APPROVAL OF CD73 MAB JAB-BX102 FROM CENTER FOR
DRUG
EVALUATION IN CHINA
Further company coverage: 1167.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Jacobio Pharmaceuticals
See all newsBrief: Jacobio Pharmaceuticals Appoints Xiaojie Wang As Vice Chairperson
China's Jacobio Pharmaceuticals H1 revenue jumps on licensing boost
Brief: Jacobio Pharmaceuticals Group Posts H1 Net Income Attributable RMB 600.6 Million
Brief: Jacobio Pharmaceuticals Expects HY Net Profit Of Not Less Than RMB600 Million
HK-listed Jacobio Pharmaceuticals climbs on share buyback plan